Oruka Therapeutics, Inc.
ORKA
$14.51
-$0.925-5.99%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 53.97% | -- | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 32.27% | 265.53% | |||
| Operating Income | -32.27% | -265.53% | |||
| Income Before Tax | -10.48% | -- | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -10.48% | -- | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -10.48% | -196.72% | |||
| EBIT | -32.27% | -265.53% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 93.40% | 97.39% | |||
| Normalized Basic EPS | 91.61% | -- | |||
| EPS Diluted | 93.40% | 97.39% | |||
| Normalized Diluted EPS | 91.61% | -- | |||
| Average Basic Shares Outstanding | 1,216.32% | -- | |||
| Average Diluted Shares Outstanding | 1,216.32% | 8,836.45% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||